EP4135788A1 - Régénérateur de dialysat comprenant un dispositif de retenue réversible - Google Patents
Régénérateur de dialysat comprenant un dispositif de retenue réversibleInfo
- Publication number
- EP4135788A1 EP4135788A1 EP21720870.1A EP21720870A EP4135788A1 EP 4135788 A1 EP4135788 A1 EP 4135788A1 EP 21720870 A EP21720870 A EP 21720870A EP 4135788 A1 EP4135788 A1 EP 4135788A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dialysate
- regenerator
- reversible
- retainer
- flow path
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002441 reversible effect Effects 0.000 title claims abstract description 210
- 238000000746 purification Methods 0.000 claims abstract description 110
- 150000002500 ions Chemical class 0.000 claims description 223
- 239000002594 sorbent Substances 0.000 claims description 70
- 238000000502 dialysis Methods 0.000 claims description 37
- 150000001768 cations Chemical class 0.000 claims description 35
- 239000012530 fluid Substances 0.000 claims description 35
- 230000008929 regeneration Effects 0.000 claims description 34
- 238000011069 regeneration method Methods 0.000 claims description 34
- 239000003053 toxin Substances 0.000 claims description 20
- 231100000765 toxin Toxicity 0.000 claims description 20
- 108700012359 toxins Proteins 0.000 claims description 20
- 150000001450 anions Chemical class 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 8
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 8
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 201000006370 kidney failure Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 230000001360 synchronised effect Effects 0.000 claims description 3
- 239000011575 calcium Substances 0.000 description 80
- 229910052791 calcium Inorganic materials 0.000 description 63
- 239000011777 magnesium Substances 0.000 description 63
- 229910052749 magnesium Inorganic materials 0.000 description 56
- 239000000463 material Substances 0.000 description 42
- 238000011045 prefiltration Methods 0.000 description 38
- 239000003792 electrolyte Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 24
- 229910019142 PO4 Inorganic materials 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 20
- 239000010452 phosphate Substances 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 230000000717 retained effect Effects 0.000 description 19
- 238000001802 infusion Methods 0.000 description 18
- 230000014759 maintenance of location Effects 0.000 description 18
- 238000001179 sorption measurement Methods 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 17
- 239000004202 carbamide Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 238000011084 recovery Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 229910052700 potassium Inorganic materials 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000002699 waste material Substances 0.000 description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- -1 ammonium ions Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000005342 ion exchange Methods 0.000 description 8
- 239000003014 ion exchange membrane Substances 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000005341 cation exchange Methods 0.000 description 6
- 229910001425 magnesium ion Inorganic materials 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 6
- LEHFSLREWWMLPU-UHFFFAOYSA-B zirconium(4+);tetraphosphate Chemical compound [Zr+4].[Zr+4].[Zr+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LEHFSLREWWMLPU-UHFFFAOYSA-B 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001631 haemodialysis Methods 0.000 description 5
- 230000000322 hemodialysis Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010019663 Hepatic failure Diseases 0.000 description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000007903 liver failure Diseases 0.000 description 4
- 231100000835 liver failure Toxicity 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 201000004193 respiratory failure Diseases 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000002441 uremic toxin Substances 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000011001 backwashing Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 229940021013 electrolyte solution Drugs 0.000 description 2
- 238000006056 electrooxidation reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000004 hemodialysis solution Substances 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1694—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid
- A61M1/1696—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid with dialysate regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/15—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with a cassette forming partially or totally the flow circuit for the treating fluid, e.g. the dialysate fluid circuit or the treating gas circuit
- A61M1/156—Constructional details of the cassette, e.g. specific details on material or shape
- A61M1/1563—Details of incorporated filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/26—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving
- A61M1/267—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving used for pumping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/166—Fluid composition conditioning, e.g. gradient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/20—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbon; comprising carbon obtained by carbonising processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/2805—Sorbents inside a permeable or porous casing, e.g. inside a container, bag or membrane
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/02—Processes using inorganic exchangers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/10—Oxides or hydroxides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/12—Compounds containing phosphorus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/02—Processes using inorganic exchangers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/10—Inorganic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/018—Granulation; Incorporation of ion-exchangers in a matrix; Mixing with inert materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/02—Column or bed processes
- B01J47/022—Column or bed processes characterised by the construction of the column or container
- B01J47/024—Column or bed processes characterised by the construction of the column or container where the ion-exchangers are in a removable cartridge
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/02—Column or bed processes
- B01J47/026—Column or bed processes using columns or beds of different ion exchange materials in series
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/12—Ion-exchange processes in general; Apparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
- A61M1/1607—Physical characteristics of the dialysate fluid before use, i.e. upstream of dialyser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
- A61M1/1609—Physical characteristics of the dialysate fluid after use, i.e. downstream of dialyser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1619—Sampled collection of used dialysate, i.e. obviating the need for recovery of whole dialysate quantity for post-dialysis analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A61M1/1635—Constructional aspects thereof with volume chamber balancing devices between used and fresh dialysis fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/62—In a cartridge
Definitions
- An aspect of the disclosure relates to a dialysate regenerator. Another aspect of the disclosure relates to a dialysis device including a dialysate regenerator. Another aspect of the disclosure relates to a medical use of the dialysate regenerator.
- Sorbent-based regenerative dialysis systems provide renal replacement therapy just like conventional dialysis systems, while using an alternative method for dialysate generation.
- Traditional, single -pass dialysis systems send spent dialysate to the drain, while sorbent-based regenerative dialysis systems allow for the regeneration and reuse of dialysate through the use of sorbent materials.
- HZO hydrous zirconium oxide
- Urea adsorber Due to the low reactivity and specificity of urea, the existing sorbent systems have to resort to a combination of enzyme catalyzed hydrolysis of urea, and subsequent adsorption of the hydrolysis product, ammonia, on a non- selective cation exchanger.
- This cation exchanger is usually zirconium phosphate (ZP), exchanging ammonium ions for sodium or hydrogen ions.
- Zirconium Phosphate however, also adsorbs other cations, most notably calcium, magnesium and potassium in exchange for sodium or hydrogen.
- This inadvertent electrolyte removal consumes cation exchange capacity (and thereby urea adsorption capacity) and impacts dialysate sodium concentration and acidity.
- electrolyte re-infusion requires a controlled pumping system adding electrolytes to the regenerated dialysate in order to re-establish the physiologically required electrolyte concentrations.
- a solution of calcium, magnesium and/or potassium ions must be infused into the regenerated dialysate.
- the dispensed solution has to be prepared by the patient before treatment, or is provided in sterilised pre-packed form.
- FIG.2 shows a cross-sectional view of a conventional device currently using sorbent regenerative technology for peritoneal dialysis
- FIG. 3 illustrates schematically the basic elements of the sorbent regeneration process.
- fresh dialysate is provided for the treatment of a patient. There, it takes up uremic solutes, electrolytes and fluid volume from the patient.
- Spent dialysate containing uremic solutes and excess electrolytes that have been removed from the patient, is then purified as it passes through the sorbent. Uremic solutes are removed and electrolytes are set to their target concentrations. This usually requires an electrolyte infusion system (enrichment solution), adding necessary electrolytes to produce a regenerated dialysate that is then returned to the patient to continue the dialysis treatment.
- electrolyte infusion system enrichment solution
- REDY sorbent-based regenerative hemodialysis device By far the most extensively used sorbent-based regenerative hemodialysis device was the REDY system, introduced in 1973. The first generation of the machine weighed 60 pounds, making it the first portable machine for home hemodialysis. [0008] The REDY sorbent cartridges provided dialysate regeneration by reprocessing used dialysate into fresh dialysate by passing it through a column of regenerative materials. The cartridge effluent was then mixed with a proportioned volume of infusate containing calcium, potassium, and magnesium to produce fresh dialysate as prescribed by the physicians.
- an electrochemical method is used to break down urea into gaseous decomposition products.
- This “electro-oxidation” however is not very specific, and parallel degradation processes form unwanted by-products which are difficult to remove and constitute significant concerns for biocompatibility or even toxicity. Further, electrode lifespan and cost have to be considered.
- a dialysate regenerator may include a purification means.
- the dialysate regenerator may include at least one reversible retainer.
- the reversible retainer may include an ion reservoir.
- the dialysate regenerator may include a dialysate flow path.
- the dialysate flow path may include a dialysate inlet for receiving a dialysate.
- the dialysate flow path may include a dialysate outlet for dispensing the dialysate.
- the dialysate regenerator may include a pump connected to the dialysate flow path.
- the pump may be configured to generate a flow of the dialysate from the dialysate inlet via the reversible retainer and the purification means to the dialysate outlet.
- a direction of the dialysate flow path through the reversible retainer may be reversible.
- the ion reservoir may include an ion exchanger.
- the dialysate regenerator may include a volume control means configured to direct a predetermined volume of the dialysate from the dialysate inlet via the reversible retainer and the purification means to the dialysate outlet.
- the ion reservoir may be in the form of particles, granules, beads, fabric, membrane, or a combination thereof.
- the ion reservoir may be a reversible ion exchanger capable of retaining and releasing ions.
- the ion reservoir may be an amphoteric ion exchanger.
- the ion exchanger may change from being predominantly an anion exchanger at a pH value of below 5 to predominantly a cation exchanger at a pH value of above 8.
- the ion reservoir may be hydrous zirconium oxide (HZO).
- HZO hydrous zirconium oxide
- the ion reservoir may be present in a quantity of less than about 50 gram (g), or less than about 20g for each of the at least one reversible retainer.
- the ion reservoir may have an average particle size in the range of about 25 micrometer to about 100 micrometer, or about 50 micrometer to about 100 micrometer.
- the ion reservoir in a pristine state may include ion salts.
- the ion reservoir may be embedded in a filter pad and/or an additional sorbent bed.
- the at least one reversible retainer may be positioned upstream of the purification means in a first direction of the dialysate flow path and positioned downstream of the purification means in a second direction of the dialysate flow path, wherein the second direction of the dialysate flow path is reverse to the first direction.
- the reversible retainer may be configured to decrease the pH of a dialysate upstream of the purification means by retaining ions from the dialysate.
- the reversible retainer may be configured to increase the pH of a dialysate downstream of the purification means by releasing ions into the dialysate.
- the dialysate regenerator may include one reversible retainer positioned upstream of the purification means in a first direction of the dialysate flow path through the reversible retainer and the same positioned downstream of the purification means in a second direction of the dialysate flow path through the reversible retainer, wherein the second direction of the dialysate flow path is reverse to the first direction of the dialysate flow path through the reversible retainer.
- the dialysate regenerator may include one or more valves for alternating the dialysate flow path between a first flow phase from the dialysate inlet to the temporary storage volume via the reversible retainer; and a second flow phase from the temporary storage volume to the dialysate outlet via the purification means and the reversible retainer, wherein a direction of the dialysate flow path through the reversible retainer in the second flow phase is reverse to the direction of the dialysate flow path through the reversible retainers in the first flow phase.
- the dialysate regenerator may include a first reversible retainer upstream of the purification means and a second reversible retainer downstream of the purification means.
- the dialysate regenerator may include one or more valves for alternating the direction of the dialysate flow path through the reversible retainer between a first direction and a second direction, the second direction being reverse to the first direction of the dialysate flow path through the reversible retainer.
- the dialysate regenerator may include a volume control means configured to direct a predetermined volume of the dialysate from the dialysate inlet via the reversible retainer and the purification means to the dialysate outlet, wherein the volume control means comprises a fluid portioning system to divide a dialysate flow into uniform portions for sequential regeneration.
- the dialysate regenerator may include one or more valves for alternating the dialysate flow path between the dialysate inlet and the dialysate outlet in a first state via the reversible retainer, the purification means, the reversible retainer and in a second state via the reversible retainer, the purification means, the reversible retainer, wherein a direction of the dialysate flow path through the reversible retainers in the second state is reverse to the direction of the dialysate flow path through the reversible retainers in the first state.
- the dialysate regenerator may include a fluid portioning system to divide a dialysate flow into uniform portions for sequential regeneration.
- the dialysate regenerator may include one or more valves for alternating the direction of the dialysate flow path through the reversible retainer between a first direction and a second direction, the second direction being reverse to the first direction.
- the dialysate regenerator may include a pressure sensor.
- the one or more valves may be synchronized and alternate the direction of the dialysate flow path through the reversible retainer upon a pressure change detected by the pressure sensor.
- the dialysate regenerator may include a temporary storage volume.
- the dialysate regenerator may include a flow adjuster, optionally comprising a pressure sensor.
- an ion reservoir in the manufacture of a dialysate regenerator including said ion reservoir included in at least one reversible retainer for the treatment of a patient suffering from renal insufficiency, liver failure or respiratory insufficiencies with abnormally high levels of one or more toxins or insufficient removal of metabolic waste products or CO2, said treatment including moving a dialysate of the patient through a dialysate flow path including a dialysate inlet for receiving a dialysate by action of a pump, a dialysate outlet for dispensing the dialysate, and a purification means, wherein a flow of the dialysate is generated from the dialysate inlet via the reversible retainer and the purification means to the dialysate outlet, wherein a direction of the dialysate flow path through the reversible retainer is reversible.
- a dialysis device including the dialysate regenerator as described above.
- a dialysate regenerator as described above for use in therapy.
- a method of treating a patient suffering from renal insufficiency, liver failure or respiratory insufficiencies with abnormally high levels of one or more toxins or insufficient removal of metabolic waste products or CO2 including moving a dialysate of the patient through a dialysate flow path including a dialysate inlet for receiving a dialysate by action of a pump, a dialysate outlet for dispensing the dialysate, and a purification means, wherein a flow of the dialysate is generated from the dialysate inlet via a reversible retainer including an ion reservoir and the purification means to the dialysate outlet, wherein a direction of the dialysate flow path through the reversible retainer is reversible.
- FIG. 1 shows a schematic for a typical sorbent cartridge used for regeneration of hemodialysate
- FIG. 2 shows a setup of a conventional sorbent-based peritoneal dialysis device
- FIG. 3 is a schematic illustrating the basic elements of a conventional sorbent regeneration process
- FIG. 4 is a schematic illustrating the basic elements of the disclosed dialysate regenerator
- FIG. 5A is a schematic showing the dialysate regenerator in accordance with some embodiments of the disclosure in a first state ST1;
- FIG. 5B is a schematic showing the dialysate regenerator in accordance with some embodiments of the disclosure in a first state ST2;
- FIG. 6A is a schematic showing the dialysate regenerator in accordance with some embodiments of the disclosure in a first state ST1;
- FIG. 6B is a schematic showing the dialysate regenerator in accordance with some embodiments of the disclosure in a first state ST2;
- FIG. 6C is a schematic of a fluid portioning system
- FIG. 7 is an illustration of the valve control principle with idealized pressure reading at PS 1 ;
- FIG. 8 is an illustration of the flow of spent dialysate through the reversible retainer
- FIG. 9 is an illustration of the flow of regenerated dialysate through the reversible retainer
- FIG. 10 is an illustration of the integration of the reversible retainer
- FIG. 11 is an illustration of the a test setup
- FIG. 12 is an illustration of the cylindrical full-size reversible retainer prototype
- FIG. 13 is an illustration of the In-vitro off-line test setup
- FIG. 14 is an illustration of the Integrated system test setup
- FIG. 15 is a graph showing the typical in-vitro behaviour of reversible retainer without pre-conditioning ;
- FIG. 16 is a graph showing the similar reversible retainer as in FIG. 15, after first pre conditioning attempts;
- FIG. 17 shows Tables of the results with the optimised reversible retainer performance
- FIG. 18 shows Tables of the results with the optimised reversible retainer performance
- FIG. 19A is a graph showing the sodium concentration in the dialysate in the HD model for an in vitro test
- FIG. 19B is a graph showing the calcium and magnesium concentration in the HD model for an in vitro test
- FIG. 19C is a graph showing the bicarbonate concentration in the HD model for an in vitro test, wherein it is shown that the initial reduction of bicarbonate is tunable, hence, if desired, the bicarbonate profile can be flattened and/or offset to higher dialysate bicarbonate concentration;
- FIG. 20 is an illustration of a schematic model (Top View) of an Integrated prototype UDRS with Infusate-free sorbent;
- FIG. 21 is an illustration of a schematic model (Bottom view) of an Integrated prototype UDRS with Infusate-free sorbent
- FIG. 22 is an illustration of a schematic model without cover (Bottom view) of an Integrated prototype UDRS with Infusate-free sorbent;
- FIG. 23 shows a Single Cylinder test setup to determine optimum air pressure setting in a pneumatic cylinder
- FIG. 24 shows a Single Cylinder test setup to determine optimum air pressure setting in pneumatic cylinder.
- the dialysate regenerator 100 may include a purification means 110.
- the dialysate regenerator 100 may include at least one reversible retainer 120.
- the at least one reversible retainer 120 may include an ion reservoir.
- the dialysate regenerator 100 may include a dialysate flow path.
- the dialysate flow path may include a dialysate inlet 130 for receiving a dialysate.
- the dialysate flow path may include a dialysate outlet 140 for dispensing the dialysate.
- the dialysate regenerator 100 may include a pump 150 connected to the dialysate flow path.
- the pump 150 may be configured to generate a flow of the dialysate from the dialysate inlet 130 via the reversible retainer 120 and the purification means 110 to the dialysate outlet 140.
- a direction of the dialysate flow path through the reversible retainer 120 may be reversible.
- dialysis may refer to hemodialysis, hemofiltration, hemodiafiltration, plasmapheresis, peritoneal dialysis, liver dialysis, lung dialysis, water purification, regeneration of physiological fluids, or regeneration of biological fluids.
- a dialysate regenerator 100 may refer to a dialysate regenerator 100 for hemodialysis dialysate, a dialysate regenerator 100 for peritoneal dialysis dialysate, a dialysate regenerator 100 for liver dialysis dialysate, a dialysate regenerator 100 for lung dialysis dialysate, a regenerator for regeneration or purification of water, a dialysate regenerator for regeneration of hemofiltrate, a dialysate regenerator for regeneration of plasma, a dialysate regenerator for regeneration of physiological fluids, or a dialysate regenerator for regeneration of biological fluids.
- the dialysate regenerator 100 may include a purification means 110, also referred to as a purification compartment.
- the purification means may include toxin removal means.
- the term ‘purification means’ may refer to a compartment that can contain one or more sorbent materials.
- the purification means may also include electro-oxidation means, electro-dialysis means or other purification means that are not based on sorbent technology.
- the compartment can be connected to a dialysate flow path.
- the sorbent materials in the purification means 110 are used for removing specific solutes from solution, such as urea.
- the purification means 110 can have a single compartmental design wherein all sorbent materials necessary for performing dialysis are contained within the single compartment.
- the purification means 110 can have a modular design wherein the sorbent materials are dispersed across at least two different modules, which can be connected to form a unitary body.
- the purification means 110 in the present disclosure may be a disposable purification means 110.
- the dialysate regenerator 100 may include at least one reversible retainer 120 including or comprising an ion reservoir.
- the term ‘reversible retainer’ may refer to a component that retains ions in one flow direction of a dialysate and releases said ions in a reverse flow direction of a dialysate.
- the reversible retainer 120 may therefore comprise an ion reservoir.
- the ion reservoir may be any chemical compound capable of retaining and releasing ions. Examples of such compounds may be an ion exchanger, an ion exchange membrane, an ion rejection membrane, etc.
- the retaining and releasing of the ions may be influenced by parameters of the dialysate, for example, by the pH value, the temperature, the pressure, the concentration, the toxin or electrolyte concentration, the density and the viscosity.
- the ion reservoir retains and releases ions dependent of the pH value.
- the term ‘ion’ when used in connection with the ion reservoir may refer to a charged atom or molecule.
- the ion may be a cation.
- the ion may be a cationic atom.
- the ion may be a physiologically essential ion.
- the ion may comprise a cation of the second group of the periodic table.
- the essential ion since the essential ion is selected from the second group of the periodic table, it has a higher valence than, for example, a cation from the first group of the periodic table.
- the higher valence affects that the cation having a higher valence may have a greater affinity for the ion reservoir or the ion exchanger contained in the reversible retainer.
- the ion may comprise calcium.
- the ion may comprise magnesium.
- the ion may comprise potassium.
- the ions, such as calcium, magnesium and potassium, may be termed essential ions, due to their physiological relevance.
- the dialysate regenerator 100 may include a pump 150.
- the term ‘pump’ is meant to refer to any pumping means.
- it may include a volume control means 115 configured to direct a predetermined volume of the dialysate from the dialysate inlet 130 via the reversible retainer and the purification means 110 to the dialysate outlet 140.
- it includes both an actuator which uses suction or pressure to move a dialysate, and a motor for mechanically moving the actuator.
- Suitable pump actuators may include an impeller, piston, diaphragm, the lobes of a lobe pump, screws of a screw pump, rollers or linear moving fingers of a peristaltic pump, or any other mechanical construction for moving dialysate. It may also include a bellow pump, gear pump, and rotary vane pump.
- the pump is connected to the dialysate flow path for pumping dialysate through the dialysate flow path from a dialysate inlet 130 for receiving a dialysate to a dialysate outlet 140 for dispensing the dialysate.
- the pump 150 may be in a feedback loop or closed loop control and may respond to pressure changes caused by variations in the dialysate flow detected at the dialysate inlet or outlet, for example at a pressure sensor. In a continuous dialysis, the pump 150 may actively regulate the flow rate of dialysate regeneration in response to fluid supply or demand detected at the dialysate inlet or outlet. The pump 150 may also be configured to operate independently and to produce a desired dialysate flow across the dialysate regenerator, for example to provide a desired dialysate flow for a dialysis treatment.
- the pump may include at least one volume control means 115, also referred to as a fluid control compartment.
- the volume control means 115 may have the form of a temporary storage volume 180.
- the volume control means 115 may have the form of a fluid portioning system 160.
- the volume control means 115 may ensure that the same concentration of essential ions is returned to the same volume of dialysate, so as to keep the concentration of essential ions constant per aliquot of dialysate.
- the dialysate entering the dialysate flow path at the dialysate inlet 130 may be termed ‘spent dialysate’ and may refer to a dialysate that contains one or more toxins, or waste species, or waste substance, such as urea. It is generally understood that it is intended to remove such one or more toxins, or waste species, or waste substance, such as urea from the spent dialysate.
- the spent dialysate may also contain one or more electrolytes or ions. In accordance with the disclosure, it may be desired to retain these electrolytes or ions in the dialysate.
- the term “retain” in context with the essential ions may refer to a substantial amount of the essential ions being retained as compared to the spent dialysate. For example, more than 80% of calcium and magnesium ions may be retained, or about 50% of potassium ions. The retention rate is dependent on the ion and/or the concentration thereof. It is desired that a fixed molecular amount of essential ions may be retained per volume of dialysate, and that any excess is allowed to pass through, which may be adsorbed in the purification means.
- the dialysate dispensed at the dialysate outlet 140 may be termed ‘fresh dialysate’ and may refer to a dialysate that is substantially free of one or more toxins, or waste species, or waste substance, such as urea.
- the fresh dialysate may also contain a desired concentration of one or more electrolytes or ions.
- the purification means 110 and the at least one reversible retainer 120 including an ion reservoir are connected via the dialysate flow path and are positioned between the dialysate inlet 130 and the dialysate outlet 140.
- the term ‘via’ does not imply a sequence of the purification means 110 and the at least one reversible retainer 120 within the dialysate flow path. However, it is understood that a dialysate may be passed through the at least one reversible retainer 120 before being passed through the purification means 110.
- the dialysate may be passed through the at least one reversible retainer 120 in a reverse direction, which may be the same reversible retainer 120 the dialysate passed through before the purification means 110, or it may be a different reversible retainer.
- the pump 150 generates a flow of the dialysate from the dialysate inlet 130 via the reversible retainer 120 and the purification means 110 to the dialysate outlet 140.
- the flow is configured to pass through the reversible retainer 120, then through the purification means 110, then through the same or another reversible retainer in a reverse direction.
- the dialysate may be configured to be passed through the at least one reversible retainer 120 at least twice, but in opposite directions, and between these at least two times the dialysate may be passed through the purification means 110. Accordingly, a direction of the dialysate flow through the reversible retainer may be reversible.
- the flow directions may be controlled by volume control means 115.
- the volume control means 115 may ensure that the volumes of dialysate are equal in both flow directions.
- the dialysate flow may be an intermittent flow, optionally a tidal flow.
- the dialysate inlet 130 for receiving the dialysate and the dialysate outlet 140 for dispensing dialysate may be combined into a single access site. Having only a single access site for both dialysate inlet 130 and dialysate outlet 140 permits for relying only on a single percutaneous access location, which minimizes the risk of infection in both the home and out-of-the-home environments.
- the pump 150 may provide for flow modes within the dialysate flow path.
- One flow mode may refer to each volume of dialysate that is passed through the dialysate flow path at one time.
- about 100 milliliter (mL) to about 500 mL, or about 150 mL to about 400 mL, or about 200 mL to about 300 mL, optionally about 250 mL of dialysate may be moved through the dialysate flow path.
- the combined amount of essential bivalent ions (e.g. calcium and magnesium) in the spent dialysate that are to be retained by the reversible retainer 120 may be below about 1 millimol (mmol), or below 0.5 mmol, or below 0.4 mmol.
- the concentration of the essential bivalent ions that are retained is about 1 to 3 mmol/L, or about 2 mmol/L.
- Such low amounts of essential ions to be retained allows for a low amount of the ion reservoir (such as the ion exchanger), which, in turn, saves on space and weight of the dialysate regenerator 100.
- the dialysate flow may be a continuous flow.
- the dialysate may typically have a flow rate through the dialysate flow path of about 100 mL/min to about 500mL/min, or about 200 mL/min to about 400 mL/min, or about 250 mL/min to about 350 mL/min. Other flow rates above and below may be considered.
- the disclosure proposes to break with the existing paradigm of inadvertent ion adsorption and the requirement for re-infusion in sorbent-based dialysate regeneration systems. This is achieved by temporary retaining essential ions (e.g., calcium and magnesium) onto at least one reversible retainer 120 containing an ion reservoir, which is simply backwashed with regenerated dialysate to retrieve the ions (see, FIG. 4).
- a dialysate flow path may provide a dialysate regenerator 100 with an improved or ameliorated control over the ions.
- the improved or ameliorated control over the essential ions may be due to the at least one reversible retainer 120 including an ion reservoir, which retains ions in the first direction of the dialysate flow path, and releases the same ions in a reverse direction of the dialysate flow in the dialysate flow path through reversible retainer 120.
- This system allows for essential ions, such as calcium and magnesium, to be retained before the dialysate is passed through the purification means 110, and to be released into the dialysate after being passed through the purification means 110.
- the dialysate regenerator 100 does not require electrolyte re-infusion, which is advantageous since it simplifies the dialysate regenerator, makes it easier to use, and allows to save on space, cost and material.
- the retention of essential ions such as calcium and magnesium avoids wasting purification means capacity for the undesired adsorption of essential ions, allowing to reduce the size and cost of the purification means. In a typical sorbent system, this may save more than 25% of the sorbent capacity, e.g. it may save 30% to 50% of the cartridge capacity, which may translate into a possible size reduction of the device by 30% to 50%.
- the retention of essential ions such as calcium and magnesium avoids excessive release of other ions, such as sodium, in exchange for calcium and magnesium, thus avoiding unwanted sodium fluctuations in regenerated dialysate, which are a key challenge for conventional sorbent systems.
- the dialysate flow path may include one or more valves (see, FIG. 4) for alternating the direction of the dialysate flow path through the reversible retainer 120 between a first direction and a second direction, the second direction being reverse to the first direction.
- the ion reservoir may comprise an ion exchange membrane, an ion exchanger, reversible precipitation means, an ion rejection membrane, or other reversible ion retention means.
- the dialysate flow flows directly through the ion reservoir, meaning that the ion reservoir is positioned between an inlet and an outlet of the reversible retainer.
- the dialysate flow is in a convective mode, and the ion exchange membrane or ion rejection membrane would also be used in a convective mode, instead of in a diffusion mode.
- the dialysate flow path does not have to undergo selective diffusion across a membrane. This allows full efficiency of purification at high exchange flow rates, low flow resistance and low cost.
- an ion exchanger may be advantageous over the use of an ion exchange membrane or ion rejection membrane, since the ion exchange membrane may have a high flow resistance and high material cost, thus presenting a serious drawback for their application together with a disposable cartridge.
- the convective mode is also particularly advantageous when using an ion exchanger in the form of particles.
- the term ‘ion exchanger’ may be molecules consisting of both a stable high molecular weight backbone structure and active ionic groups.
- the backbone provides stability, insolubility, and structure, while the active groups provide ion exchange properties.
- the backbone may include any element or combination of elements that can be joined together to form long, preferably branched chains or 3 -dimensional networks.
- the ion exchanger may comprise an organic ion exchanger and an inorganic ion exchanger.
- the ion exchanger may be crystalline or amorphous.
- the property of insolubility imparted by this backbone structure may account for the nontoxicity of these agents. Since the ion exchanger is not soluble, it is not dissolved when used in dialysate regeneration.
- the ion exchanger may comprise active groups, optionally selected from negatively charged anionic groups or positively charged cationic groups.
- the negatively charged groups may comprise sulfonate groups, carboxy groups, sulfate, sulfinate, phosphate, phosphonate, phosphinate, hydroxide, sulfide, (metal) oxyanions.
- the positively charged groups may comprise amino groups (primary, secondary, tertiary, qatemary, imino, zeolites (aluminosilicates), metal oxides, hydrous metal oxides, acidic salts of polyvalent metals, insoluble salts of heteropolyacids.
- the active groups determine the major properties of the ion exchangers.
- Positive groups such as quaternary amines attached to the backbone impart a positive charge that is balanced by negatively charged mobile anions. These anions can be exchanged, and such compounds correspondingly represent anion exchangers.
- Amphoteric ion exchangers have both negative and positive active groups and can exchange both cations and anions.
- the ion exchanger may be present as porous structures. The porosity, the pore size, and the number and type of active group's represent the major determinants of the sorbents function. Ion exchangers may be viewed as electrolyte sponges. With greater selectivity coefficient for a certain cation, more of this cation will be bound as compared to a cation with lower selectivity. Most cation exchangers show the following selectivity for physiologically significant cations: Li ⁇ Na ⁇ K ⁇ NH4 «Mg ⁇ Ca.
- Ca 2+ has the greatest affinity for a typical cation exchanger.
- affinity is generally directly related to molecular weight. This specificity order means that a dialysate exchange process will result in calcium adsorption if calcium is present in the biologic fluid. This may result in unwanted consumption of adsorptive capacities and depletion of ions whose removal is not part of the intended therapeutic goal.
- biologic fluids are polyelectrolyte solutions, ion exchanger design for specific clinical purposes is limited by the nonspecificity of the exchange process and the relative affinities of the various ions for the exchangers.
- the affinity may vary with different ion exchangers and may, within limits, be modified by the processes used to synthesise or pretreat ion exchangers prior to use.
- the maximum capacity of an ion exchanger (i.e. its exchange potential or efficiency) is determined by the number of active groups, usually expressed in milliequivalents per gram of exchanger. This capacity can be determined by titrating the ion exchanger, just as is done in determining the concentration of an acid or base. However, the capacity for the desired ion under actual conditions of clinical use is of even greater practical interest. This is usually determined empirically under the actual conditions of use.
- the capacity of the ion exchanger for the ion to be adsorbed may not only be dependent upon the theoretical capacity but also upon the selectivity coefficient and concentration of the ion to be removed. Competitive binding by other ions may also limit achieving full theoretical capacity.
- the action of certain ion exchangers may also be pH dependent, thereby limiting medical application to those, which are active either at or near the pH of body fluids. Such dependencies can be exploited to achieve reversible ion adsorption.
- the total exchange capacity for a cation with comparatively low selectivity coefficient is strongly dependent on the cation’s concentration. In consequence, this cation may be adsorbed from more concentrated solutions, and desorbed into more diluted solutions.
- the capacity of the ion exchanger according to this disclosure may be selected such that the essential ions are not quantitatively retained. Accordingly, the dialysate, after passing through the reversible retainer 120 for the first time, may still contain some of the essential ions, which are subsequently absorbed in the purification means 110.
- the capacity may for example be selected such that an undesired excess of essential ions is allowed to pass through the retainer, such that the excess will be adsorbed in the purification means 110.
- this can be used to correct patient imbalances, where the patient suffers from excess concentration of the essential ions.
- the ion exchanger may be a cation exchanger or an anion exchanger.
- the ion reservoir may be in the form of particles, granules, beads, fabric, membrane, or a combination thereof.
- the ion reservoir may be a reversible ion reservoir capable of retaining and releasing ions.
- the ion reservoir may comprise an amphoteric ion exchanger.
- the ion exchanger may change from being predominantly an anion exchanger at a pH value of below about 5, or below about 6, or below about 7.
- the ion exchanger may change from being predominantly a cation exchanger at a pH value of about above 8, or about above 7, or about above 6.
- the ion exchanger may be an amphoteric ion exchanger and change its behavior according to pH value
- the ion exchanger is capable of retaining ions at a certain pH value of the dialysate and releasing ions at a different pH value of the dialysate.
- the dialysate before passing through the at least one reversible retainer 120 and/or the purification means 110 may have a different pH value than the dialysate after passing through the purification means 110 and flowing towards the at least one reversible retainer 120 in the reverse direction.
- some essential ions may have a higher affinity for retention dependent on the pH of the dialysate.
- the affinity of calcium (Ca) vs protons is dependent on pH value. At a high pH value (or a high calcium concentration), calcium is bound and protons are released. At low pH values (or low Ca concentration), protons are bound and Ca is released.
- the disclosure exploits two features that result in the synergistic effect of retaining and releasing ions from the dialysate, which obviates the need for an electrolyte re-infusion.
- the amphoteric character of the ion exchanger causes the reversible retainer 120 to retain essential ions in one flow direction and to release these essential ions in the reverse direction.
- the pH value of the dialysate decreases after being passed through the reversible retainer 120 and the purification means 110.
- dialysate returning from the purification means 110 has generally a slightly lower pH (approximately 6.5 - 7.2) than dialysate coming from the patient (approximately 7.4).
- the exchange of essential ions (such as Ca and Mg) for H and Na in the reversible retainer 120 already lowers the pH of the spent dialysate entering the purification means 110.
- the dialysate exiting the purification means 110 has a formally increased pCCk, resulting in a further slight decrease of pH value of the dialysate.
- the ion exchanger may be hydrous zirconium oxide (HZO).
- HZO may generally be considered an anion exchanger. It is used in dialysate regeneration and water purification to adsorb phosphate, fluoride and other potentially harmful anions. It was found that HZO also has amphoteric character, exchanging anions at pH ⁇ 7, and cations at pH>7.
- the ion exchange properties can be represented by the following Scheme: m alkaline solution R OH 4 OH 1 R Q ⁇ 4 HOH
- HZO appears to be unique in that it has a high degree of homogeneity of active groups within the matrix of HZO, which may advantageously allow for a finely tunable pH dependency of the reversability of the ion exchange process. This property was likely the key factor for the very good results obtained with this material.
- the ion reservoir may be embedded in a filter pad. Additionally or alternatively, the ion reservoir may be embedded in an additional sorbent bed.
- the ideal arrangement for the reversible retainer 120 including the ion reservoir may be in a small sorbent bed, which is in sequential arrangement to the purification means 110 such that both, spent dialysate delivered to the main sorbent and fresh dialysate returning from the purification means 110 has to pass through this sorbent bed, using direct filtration in two distinct flow modes.
- direct filtration is highly efficient with low flow resistance and high fluid exchange and purification rates. It is suitable for cost efficient miniaturization and opens the way to the development of the first sorbent dialysis system, which does not depend on electrolyte re-infusion.
- the ion reservoir may be comprised in the reversible retainer 120 in a quantity of less than about 50 gram, or less than 20 gram (g), or less than about 15 g, or less than about 10 g, or less than about 5 g, for each of the at least one reversible retainer 120.
- g the number of grams in the reversible retainer 120.
- such low amounts of the ion reservoir may be advantageous in reducing the overall size of the dialysate regenerator 100.
- the ion reservoir may have an average particle size in the range of about 25 micrometer to about 100 micrometer, or about 50 micrometer to about 100 micrometer. Such particle size ranges may be obtained by sieving the ion reservoir material prior to use.
- a particle size range of about 25 micrometer to about 100 micrometer, and more preferably of about 50 micrometer to about 100 micrometer gave the lowest pressure drop and fastest achievable dialysate flow rates.
- the ion reservoir in a pristine state may refer to an ion reservoir prior to its first use.
- the ion reservoir in a pristine state may include essential ions.
- the essential ions may be included in the ion reservoir subsequent to a pretreatment with ion salts, and the ion reservoir may accordingly be preloaded with the essential ions.
- the ion salts may be the salts of the same ions that are to be retained and released in the ion reservoir.
- the ion reservoir in a pristine state includes essential ions, one of the key challenges for optimization, namely the tendency of the ion reservoir to undergo gradual changes during use, can be avoided.
- ion retention rates such as Ca and Mg retention rates, were low at the beginning of the experiments and only reached satisfactory levels after lengthy periods of stabilization ⁇
- the ion exchanger may comprise a preselected percentage of essential ions, such as Ca and Mg.
- the preselected percentage may be a percentage of 0.1 to 10 wt% of Ca and/or Mg.
- the at least one reversible retainer 120 may be positioned upstream of the purification means 110 in a first direction of the dialysate flow path through the reversible retainer and positioned downstream of the purification means 110 in a second direction of the dialysate flow path through the reversible retainer, wherein the second direction of the dialysate flow path is reverse to the first direction.
- the reversible retainer 120 may decrease the pH value of a dialysate upstream of the purification means 110 by retaining ions from the dialysate.
- the reversible retainer 120 may increase the pH value of a dialysate downstream of the purification means 110 by releasing ions into the dialysate.
- the dialysate regenerator 100 may include one reversible retainer 120. Said one reversible retainer 120 may be positioned upstream of the purification means 110 in a first direction of the dialysate flow path through the reversible retainer and the same reversible retainer may be positioned downstream of the purification means 110 in a second direction of the dialysate flow path through the reversible retainer, wherein the second direction of the dialysate flow path is reverse to the first direction.
- This embodiment is illustrated in FIG. 4.
- the dialysate regenerator 100 may include a first reversible retainer 120A upstream of the purification means 110 and a second reversible retainer 120B downstream of the purification means 110.
- the dialysate regeneration may be carried out in sequential regeneration, and may include two alternate states including a first state and a second state.
- FIG. 5A and FIG. 5B shows two alternate states.
- FIG. 5A shows a first state, ST1, wherein dialysate, containing essential ions and toxins, passes through a first reversible retainer 120A.
- the essential ions are retained at the ion reservoir comprised in reversible retainer 120A.
- the dialysate then passes through the purification means 110, wherein toxins are removed from the dialysate.
- the dialysate then passes through the reversible retainer 120B and essential ions previously retained by reversible retainer 120B are released into the dialysate.
- FIG. 5B shows a second state, ST2, with a reversed flow direction through the reversible retainers.
- dialysate containing essential ions and toxins passes through a first reversible retainer 120B.
- the essential ions are retained at the ion reservoir comprised in reversible retainer 120B.
- the dialysate then passes through the purification means 110, wherein toxins are removed from the dialysate.
- the dialysate then passes through the reversible retainer 120A and essential ions previously retained by reversible retainer 120A are released into the dialysate.
- the reversible retainers 120 A and 120B function as either retaining or releasing the essential ions, wherein each of the reversible retainers 120A and 120B retain the essential ions in a first direction upstream of the purification means 110, and release the essential ions in a second direction downstream of the purification means 110, i.e. in a reverse direction.
- This arrangement allows to effectively run the regeneration in a continuous flow of dialysate, which is divided (portioned) into the two alternating states.
- the dialysate regenerator 100 may additionally include a fluid portioning system 160 (see, FIG. 6C) which may also function as a pump, to divide a dialysate flow into uniform portions for the sequential regeneration.
- the fluid portioning system 160 may include divide a dialysate flow into uniform portions for sequential regeneration.
- the dialysate regenerator 100 may additionally include one or more valves.
- the valves may include two sets of inverting valve arrangements.
- one or more valves, or one set of valves may alternate the direction of the dialysate flow path direction through the reversible retainer 120 between a first direction and a second direction, the second direction being reverse to the first direction.
- a further one or more, or one set of valves may alternate the direction of the dialysate flow path direction between the fluid portioning system 160 and the dialysate outlet 140 for dispensing the dialysate.
- the dialysate regenerator 100 may additionally include one or more pressure sensors.
- the one or more pressure sensor may detect the external pressure at the volume control means 115, for example the pressure sensor may include the pressure sensor PS1 illustrated in FIG. 6A and FIG, 6B.
- One of the pressure sensors e.g. PS2
- PS2 may be positioned in the dialysis flow path upstream of the purification means 110. This sensor may be used to detect a change of pressure or dialysate flow entering the dialysate inlet, and to regulate a pump accordingly.
- Another of the pressure sensors may be positioned in the dialysis flow path between purification means and fluid portioning system.
- the two sets of inverting valve arrangements may be synchronised and triggered by detection of a pressure increase at this pressure sensor.
- the pressure sensor for example, pressure sensor PS2
- PS2 may be positioned downstream of the fluid portioning system. This sensor may be used to detect a change of pressure or dialysate flow withdrawn from the dialysate outlet, and to regulate a pump accordingly.
- the purification means 110 may be connected to the dialysate flow path in such a way that it only receives dialysate which has previously passed through one of the reversible retainers 120A or 120B, while releasing dialysate through the other reversible retainers 120A or 120B.
- FIG. 6A and FIG. 6B illustrate an embodiment wherein the valves are connected to the pressure sensor 170 (PS1) and the fluid portioning system. With each detection of a pressure increase at a pressure sensor PS 1 (see FIG. 6B, FIG. 7), the system inverts the flow direction through V1/V2 and V3/V4.
- the flow conduit system is thereby arranged in such a way that the dialysate flow direction through the purification means 110 is never changed, while the dialysate flow direction through the reversible retainers 120A or 120B is regularly inverted, after equal portions of dialysate are defined by the portioning system.
- an equivalent volume of previously regenerated and reconstituted dialysate is released from a second compartment of the fluid portioning system 160 through VI, and is delivered to the HD machine as fresh dialysate.
- the spent dialysate drained from the HD machine is passed through V4 to reversible retainer 120B, the reversible retainer which was previously backwashed in ST1.
- Reversible retainer 120B adsorbs all essential ions from spent dialysate prior to its de-toxification in the purification means 110.
- the de-toxified dialysate exiting the purification means 110 is guided to back- wash reversible retainer 120A and to release all essential ions bound in the previous ST1.
- the dialysate regenerator 100 may include a temporary storage volume 180.
- the temporary storage 180 volume is located upstream of said purification means 110.
- the function of the temporary storage volume is to accommodate the tidal volume. In some embodiments, it may also be used as a portioning system, and/or as a pump.
- the dialysate regenerator 100 may include sensing means, or a substance sensor.
- the sensing means may be configured to detect potentially harmful conditions in the regenerated dialysate.
- potentially harmful conditions may include excessive concentrations of ammonia or potassium in regenerated dialysate. Due to the presence of the sensing means, the electronic control of the dialysate regenerator will be able to detect an alarm condition and produce appropriate steps such as stopping the therapy and/or alerting the user.
- the dialysate regenerator 100 may include control electronics.
- the control electronics may be configured to control the operation of said dialysate regenerator 100.
- There may also be provided an interface means capable of operably coupling the control electronics and the dialysate regenerator 100 to enable the removal of toxins from the dialysate.
- the dialysate flow path may be fluidly sealed from the control electronics and interface means.
- the at least one reversible retainer 120 including the ion reservoir may be part of a disposable system, or could even become a non-disposable permanent component of a dialysate regenerator 100. As it is continuously regenerated, the ion reservoir in the reversible retainer 120 would not be expected to exhaust. On the contrary, re-use of a reversible retainer 120 including the ion reservoir may be of advantage for a continuous dialysis therapy, as this will eliminate the stabilisation period (as described further above).
- Embodiments described in the context of the dialysate regenerator 100 are analogously valid for the context of the dialysis device. Similarly, embodiments described in the context of the dialysate regenerator 100 are analogously valid for a medical use of the dialysate regenerator 100, and vice-versa.
- an ion reservoir in the manufacture of a dialysate regenerator 100 including said ion reservoir included in at least one reversible retainer 120 for the treatment of a patient suffering from renal insufficiency, liver failure or respiratory insufficiencies with abnormally high levels of one or more toxins or insufficient removal of metabolic waste products or CO2, said treatment including moving a dialysate of the patient through a dialysate flow path including a dialysate inlet 130 for receiving a dialysate by action of a pump, a dialysate outlet for dispensing the dialysate, and a purification means 110, wherein a flow of the dialysate is generated from the dialysate inlet via the reversible retainer 120 and the purification means 110 to the dialysate outlet 140, wherein a direction of the dialysate flow path through the reversible retainer 120 is reversible.
- a dialysis device 200 including the dialysate regenerator 100 as described above.
- a dialysate regenerator 100 as described above for use in therapy.
- a method of treating a patient suffering from renal insufficiency, liver failure or respiratory insufficiencies with abnormally high levels of one or more toxins or insufficient removal of metabolic waste products or CO2 including moving a dialysate of the patient through a dialysate flow path including a dialysate inlet 130 for receiving a dialysate by action of a pump 150, a dialysate outlet 140 for dispensing the dialysate, and a purification means 110, wherein a flow of the dialysate is generated from the dialysate inlet 130 via a reversible retainer 120 including an ion reservoir and the purification means to the dialysate outlet 140, wherein a direction of the dialysate flow path through the reversible retainer 120 is reversible.
- Some embodiments of this disclosure are directed to substantially quantitatively adsorb and desorb calcium and magnesium ions on a reversible retainer 120, which may be termed “pre-filter” in the present section.
- the ion exchanger used herein may exert a weak binding attraction to Ca and Mg ions. It may be, for example, a weakly acidic cation exchanger.
- the cation exchanger may have an acid dissociation constant (pKa) in the range of 3 to 10, or optionally in that range of the pH value of the dialysate, i.e. close to physiological range (pKa 5 - 8).
- the ion exchanger may be in the form of particles, granules, beads, fabric or membranes.
- hydrous zirconium oxide is a granular material that has weak cation exchange properties (besides its anion exchange properties) in the desired range.
- the pre-filter may have sufficient binding capacity to adsorb the desired amount of Ca and Mg ions contained in the volume of dialysate pumped during each flow mode. Its capacity may be chosen such that excess amounts of Ca and Mg are deliberately “overflowing” the pre-filter into the main sorbent, where they will be adsorbed. The physical dimension of the filter can thereby still remain quite small. For example, a total of 250 ml dialysate may be moved in each flow mode. This volume then contains only a combined total of approximately 0.35mmol of Ca and Mg. This requires at most a few grams of a typical ion exchanger material, and may for example be achieved by a single layer of an ion exchange fabric pad, or an ion exchange membrane.
- the pre-filter may quantitatively (or substantially quantitatively) release the bound cations upon backwashing with regenerated dialysate. This may be effected by the changed ion concentration of Ca and Mg in regenerated dialysate.
- the sorbent regeneration of dialysate also produces typical pH fluctuations, which can be exploited to support the Ca and Mg adsorption and desorption process.
- Dialysate returning from the sorbent has generally a slightly lower pH (approximately 6.5 - 7.2) than dialysate coming from the patient (approximately 7.4).
- the exchange of Ca and Mg for H and Na in the pre-filter already lowers the pH of the spent dialysate entering the sorbent system.
- the dialysate exiting the sorbent has a formally increased pCCk, resulting in a further slight decrease of pH. This lower pH facilitates the reversed exchange of H and Na against Ca and Mg in the pre-filter. At the same time, the dialysate’ s pH is slightly increased and moves closer to the physiological target of 7.4.
- FIG. 8 and FIG. 9 show a schematic diagram for a possible arrangement of pre filter, temporary storage volume and purification means in a proposed dialysate regenerator for a tidal peritoneal dialysis machine.
- the dialysate is pressed out of the temporary storage volume and through the sorbent system where uremic toxins and K are adsorbed to >90%.
- the toxin-free dialysate leaving the sorbent system is essentially free of uremic toxins, and contains almost exclusively Na, Cl and HCO3 ions.
- the check-valves in the flow circuit then serve to guide this solution through the pre-filter, in opposite flow direction as in the “Outflow” phase. In doing so, all bound Ca and Mg is exchanged by H and Na and re-dissolved into the dialysate.
- the dialysate returning to the patient thus has the same amount of Ca and Mg as the dialysate that was withdrawn from the patient.
- FIG. 2 shows a conventional sorbent-based PD system.
- FIG. 10 depicts a proposed modification of the existing design to implement a pre-filter. The main changes are one additional flow channel and two additional check-valves to ensure correct flow directions in the two flow phases. As the infusate system becomes obsolete, it may be removed and the sorbent system may be expanded accordingly.
- a smaller version of the infusate system may be maintained to infuse a concentrated solution of an osmotic agent such as e.g. a commercial glucose solution.
- an osmotic agent such as e.g. a commercial glucose solution.
- the infusion of osmotic agent may be regulated independently of the main dialysate pumping rate. This opens the possibility of a future sensor-regulated control of the osmotic pressure of the dialysate.
- electrolyte re-infusion is a major drawback of existing sorbent- based dialysate regeneration systems. It is cumbersome to use and complicated to implement, poses a potential safety risk, and it increases the size and cost of disposables.
- the objective of this disclosure is to find a way to re-use established and proven-to- be-safe sorbent technology, while eliminating the requirement for electrolyte re-infusion.
- the new approach should simplify existing designs, eliminate regulatory obstacles and provide a safe pathway for new, cost efficient miniaturised devices.
- This disclosure aims to provide a new technique for selective and efficient sorbent dialysate regeneration without the requirement for electrolyte re-infusion. This is achieved by reversible binding of essential electrolytes on a suitable pre-filter material, such as an ion exchanger. Calcium and magnesium-free dialysate is then regenerated on a conventional sorbent system. The pre-filter is washed back with regenerated dialysate, dissolving the retained electrolytes in the process, and effectively re-constituting the dialysate to its initial electrolyte concentration.
- a suitable pre-filter material such as an ion exchanger.
- Calcium and magnesium-free dialysate is then regenerated on a conventional sorbent system.
- the pre-filter is washed back with regenerated dialysate, dissolving the retained electrolytes in the process, and effectively re-constituting the dialysate to its initial electrolyte concentration.
- the new approach has the potential to provide significant design simplifications of disposable components of sorbent dialysis machines. It allows the development of miniaturized self-care dialysis machines of high marketing potential, increasing patient comfort, safety and efficacy of treatment at a lower cost than existing devices.
- a re usable cylindrical 040mm prototype cartridge was packed with a 5 - 10 mm layer of ion exchanger.
- Membrane ion exchangers were fixed in a re-usable 24 mm diameter disk membrane holder.
- the idealised outflow solution was a bicarbonate buffered dialysate solution at pH 7.5, containing no toxins and no glucose.
- the idealised inflow solution was a solution of only NaCl and NaHC0 3 at pH 6.3 to 6.5.
- a suitable pre-filter material would have been characterised by approximately quantitative adsorption of Ca and Mg from the “dialysate outflow”, and approximately quantitative recovery of Ca and Mg in the “dialysate inflow”. Beyond that, factors like binding capacity and flow resistance were taken into account.
- Table 1 shows a summary of the obtained screening results with a selection of different ion exchange materials. It should be noted that only a limited number of materials was used, and that other materials within the tested categories may be found which may perform differently. The assessment of suitability should therefore only be interpreted for the particular material samples tested, and not for entire material categories.
- Zirconium Phosphate was an obvious candidate to be tested in this study, being the cation exchanger used in the current conventional sorbent systems. Its cation exchange properties are based on interactions with phosphate groups at a wide pH range spanning from pH2 - pH8. Its performance as pre-filter material was not satisfactory, however. This is believed to be due to its significantly higher affinity to Ca and Mg, relative to Na and H, possibly due to complex formation. In other words, H was unable to dislodge Ca and Mg from its binding sites to any significant amount. The resulting retention rates for Ca and Mg were too low to be useful for pre-filter application.
- Carboxylic acid based ion exchangers The majority of weakly acidic cation exchangers rely on the action of carboxylic acid functional groups, which bind to H or other cations. Their pK of 3 - 5 means that the typical pH fluctuations in dialysate regeneration would effect significant changes in the protonation grade of the material, which is an essential requirement for reversible ion exchange in this study.
- Ion exchange membranes were reasonably high binding capacity and recovery efficiency. However, their high flow resistance and high material cost were a serious drawback for their application in a disposable cartridge.
- Hydrous Zirconium Oxides Hydrous zirconium oxide is generally considered an anion exchanger, which exchanges hydroxide or acetate against other anions, such as e.g. phosphate or fluoride. However, it has also cation exchange properties, which became apparent during material tests, where not only the actual target, phosphate, was removed, but unexpectedly also Ca and Mg. The assumed mechanisms for anion and cation exchange are depicted in Scheme 1. Thus, while anion exchange involves the dissociation of Zr-0 bonds, cation exchange involves the dissociation of ZrO-H bonds.
- Table 2 is a Table showing the reversible retainer performance after optimised preconditioning conditions for 5g Pre-Treated Type I, 250mL
- HZO filter pad The investigation of HZO filter pads was done in an attempt to get away from a fixed particle bed, to a pre-filter containing HZO fixed on a 3 dimensional scaffold (filter pad). The flow resistance of such filter pads is primarily determined by the structure of the cellulose support. Filter pads do also have significant advantages for ease of assembly.
- a suitable filter pad manufacturing procedure was, for example, to mix 5.6g of filter paper (small pieces) and 37.56g of HZO in a solution of 2.87g NaCl, 1.49g NaHC0 3 14.37g CaCh and 1.06g gCF. This mixture was mechanically stirred until a homogenous mash was obtained. Then, 1.40g dextrin, 0.06g starch, 0.37g sodium carboxymethyl cellulose and O.Olg sodium benzoate was added. Casting and drying provided 4 HZO filter pads.
- pre-filter size Optimisation of pre-filter size.
- the next step of development involved the optimisation of pre-filter capacity and dimensions. This was done with component-level prototypes, which were either run off-line using idealised dialysate solutions, or in-line in conjunction with conventional sorbent cartridges. In an initial phase, it was attempted to attain complete retention of the desired target concentrations of Ca and Mg, while removing any excess. In the course of these efforts, it became clear that the pre-filters also had a tendency for partial adsorption of K and phosphate during outflow, which were then equally desorbed during inflow, resulting in a partial retention of those undesired components. Larger sized pre-filters provided increased Ca and Mg retention rates, but also reduced K and phosphate removal rates (for example 80 g, see, Table 3).
- Table 3 is a Table showing the IV performance of a large size reversible retainer, 80g Pre-Treated Type I, 250mL
- Table 4 Table showing the IV performance of a small size reversible retainer, lOg Pre-Treated Type I, 250mL
- Table 5 is a Table showing the optimised reversible retainer size IV performance, lOg Type I, 250mL
- Example 4 Embodiment with at least two reversible retainers
- All test cartridges were used in both flow directions (see, FIG. 11). First, an idealised “dialysate outflow” solution was passed through the test cartridge in one direction, Ca and Mg was detectable in the fluid exiting the cartridge (“saline outflow”). Then the cartridge was turned around, and the same volume of idealised “saline inflow” solution was passed through in opposite direction. The fluid exiting the cartridge in this direction (“dialysate inflow”) was again assayed for Ca and Mg.
- the idealised outflow solution was a bicarbonate buffered dialysate solution at pH 7.3 to 7.5, containing no toxins and no glucose.
- the idealised inflow solution was a solution of only NaCl and NaHC0 3 at pH 6.3 to 6.5. Desired material properties were approximately quantitative adsorption of Ca and Mg from the “dialysate outflow”, and approximately quantitative recovery of Ca and Mg in the “dialysate inflow”. Beyond that, other factors like flow resistance were taken into account.
- Each direction control valve (VI, V2, V3 and V4) in the integrated cartridge consisted of a rigid flow chamber, which was sealed by a flexible PVC membrane on one side (see, FIG. 23 and FIG.24).
- the flow chamber had a fluid inlet channel and a fluid outlet channel.
- the inlet channel was located in close proximity to the flexible PVC membrane, such that pressing the flexible membrane onto the inlet channel opening could seal the channel.
- the pressing was done with the help of pneumatic cylinders (one for each valve), which were equipped with silicone plungers.
- the valves were thus naturally open 2/2 valves, which could be closed by activating the pneumatic plungers.
- the optimum pressure setting for the pneumatic cylinder was determined for different fluid pressures and silicone plunger diameters.
- the preferred pneumatic cylinder was CJ2B6 from SMC as the size was deemed suitable in the whole integration design.
- the diameter of the valve inlet channel was 3mm (Inner Diameter) and 6mm (Outer Diameter). The test results are shown in the Table 7 below:
- Table 8 Summary of Infusate-free sorbent system performance at various concentration ranges
- FIG. 19A, FIG. 19B, FIG. 19C are identical to FIG. 19A, FIG. 19B, FIG. 19C.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- External Artificial Organs (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
- Gloves (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10202003363P | 2020-04-13 | ||
SG10202003365X | 2020-04-13 | ||
SG10202003361W | 2020-04-13 | ||
PCT/SG2021/050208 WO2021211060A1 (fr) | 2020-04-13 | 2021-04-13 | Régénérateur de dialysat comprenant un dispositif de retenue réversible |
Publications (3)
Publication Number | Publication Date |
---|---|
EP4135788A1 true EP4135788A1 (fr) | 2023-02-22 |
EP4135788C0 EP4135788C0 (fr) | 2024-05-29 |
EP4135788B1 EP4135788B1 (fr) | 2024-05-29 |
Family
ID=75639959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21720870.1A Active EP4135788B1 (fr) | 2020-04-13 | 2021-04-13 | Régénérateur de dialysat comprenant un dispositif de retenue réversible |
EP21721241.4A Active EP4135789B1 (fr) | 2020-04-13 | 2021-04-13 | Régénérateur de dialysat et système le comprenant |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21721241.4A Active EP4135789B1 (fr) | 2020-04-13 | 2021-04-13 | Régénérateur de dialysat et système le comprenant |
Country Status (6)
Country | Link |
---|---|
US (2) | US20230347031A1 (fr) |
EP (2) | EP4135788B1 (fr) |
CN (2) | CN115916285A (fr) |
AU (2) | AU2021255340A1 (fr) |
CA (2) | CA3180135A1 (fr) |
WO (2) | WO2021211061A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023097256A1 (fr) * | 2021-11-24 | 2023-06-01 | University Of Washington | Systèmes et procédés d'hémodialyse conservant l'eau |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9415150B2 (en) * | 2007-11-09 | 2016-08-16 | Baxter Healthcare S.A. | Balanced flow dialysis machine |
US20140158588A1 (en) * | 2012-12-10 | 2014-06-12 | Medtronic, Inc. | pH AND BUFFER MANAGEMENT SYSTEM FOR HEMODIALYSIS SYSTEMS |
EP2950836B1 (fr) * | 2013-02-01 | 2019-11-06 | Medtronic, Inc. | Cartouche de sorbant pour mesurer des concentrations de soluté |
EP3352811B1 (fr) * | 2015-09-25 | 2020-12-09 | Medtronic Inc. | Systèmes de dialyse à régénération à base de sorbant sélectif |
WO2018106185A2 (fr) * | 2016-12-05 | 2018-06-14 | Temasek Polytechnic | Sorbant pour dispositif de dialyse et système de dialyse |
-
2021
- 2021-04-13 CA CA3180135A patent/CA3180135A1/fr active Pending
- 2021-04-13 AU AU2021255340A patent/AU2021255340A1/en active Pending
- 2021-04-13 WO PCT/SG2021/050209 patent/WO2021211061A1/fr active Search and Examination
- 2021-04-13 EP EP21720870.1A patent/EP4135788B1/fr active Active
- 2021-04-13 CA CA3180137A patent/CA3180137A1/fr active Pending
- 2021-04-13 CN CN202180042457.7A patent/CN115916285A/zh active Pending
- 2021-04-13 AU AU2021255746A patent/AU2021255746A1/en active Pending
- 2021-04-13 US US17/918,825 patent/US20230347031A1/en active Pending
- 2021-04-13 EP EP21721241.4A patent/EP4135789B1/fr active Active
- 2021-04-13 CN CN202180042852.5A patent/CN115835893A/zh active Pending
- 2021-04-13 WO PCT/SG2021/050208 patent/WO2021211060A1/fr active Search and Examination
- 2021-04-13 US US17/918,818 patent/US20240058514A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115835893A (zh) | 2023-03-21 |
CA3180135A1 (fr) | 2021-10-21 |
EP4135788C0 (fr) | 2024-05-29 |
EP4135789A1 (fr) | 2023-02-22 |
EP4135789C0 (fr) | 2024-05-29 |
EP4135789B1 (fr) | 2024-05-29 |
WO2021211060A1 (fr) | 2021-10-21 |
AU2021255340A1 (en) | 2022-11-17 |
CN115916285A (zh) | 2023-04-04 |
CA3180137A1 (fr) | 2021-10-21 |
US20230347031A1 (en) | 2023-11-02 |
US20240058514A1 (en) | 2024-02-22 |
WO2021211061A1 (fr) | 2021-10-21 |
AU2021255746A1 (en) | 2022-11-24 |
EP4135788B1 (fr) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11911546B2 (en) | System for removing uremic toxins in dialysis processes | |
EP2446908B1 (fr) | Dispositif d'électrosorption et décomposition pour la purification du sang et d'autres fluides | |
US20220401634A1 (en) | Sorbent for a dialysis device and dialysis system | |
JP3956363B2 (ja) | 透析液を洗浄するのに有用なカートリッジ | |
JP2004525747A5 (fr) | ||
EP4135788B1 (fr) | Régénérateur de dialysat comprenant un dispositif de retenue réversible | |
US20220161233A1 (en) | Sorbent for use in renal therapy | |
US20230108155A1 (en) | Portable and wearable drug delivery system | |
RU2785326C2 (ru) | Сорбент для устройства для диализа и системы для диализа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221114 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01J 47/00 20170101ALI20231027BHEP Ipc: B01J 41/10 20060101ALI20231027BHEP Ipc: B01J 41/02 20060101ALI20231027BHEP Ipc: B01J 39/12 20060101ALI20231027BHEP Ipc: B01J 39/02 20060101ALI20231027BHEP Ipc: B01J 39/00 20060101ALI20231027BHEP Ipc: B01J 20/20 20060101ALI20231027BHEP Ipc: A61M 1/28 20060101ALI20231027BHEP Ipc: A61M 1/16 20060101AFI20231027BHEP |
|
INTG | Intention to grant announced |
Effective date: 20231117 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021013839 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20240610 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240618 |